Developer docs
API playgroundTry for free, no card

Search company profiles

Oddifact

Full company profile

uuid003q2ah

Namestring
Oddifact
Legal namestring
Oddifact
Websiteurl
oddifact.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Oddifact is a privately held French biotech technology company headquartered in Paris that operates an artificial intelligence platform for drug repositioning in rare diseases. The platform identifies orphan drug applications for existing medicines, validates candidates, and accelerates regulatory pathways to convert off-label use into approved orphan drug designations. The company claims 73% workflow automation through AI and the ability to move from candidate selection to FDA submission in 10 days, with an operational track record of 11 granted Orphan Drug Designations across the US and Europe, 16 FDA submissions, and a #1 global ranking for FDA Orphan Drug Designations in 2024. Its pipeline is organized around repositioning established molecules such as infliximab (for IVIG-resistant Kawasaki disease) and the MabionCD20 antibody (under a 2026 letter of intent with Mabion S.A.), with a stated ambition of 30-50 new rare disease treatments by 2030.

The business model is B2B, targeting pharmaceutical and biotech companies through direct enterprise partnerships and strategic co-development agreements, with revenue expected to derive from licensing, royalties, and milestone payments. The company operates with 11-50 employees and is founder-led by Pierre-Alexandre Teulié, with no disclosed external institutional investors, funding rounds, or revenue figures. Distribution is conducted through direct field sales and high-profile industry engagement (e.g., Digital Health & AI Innovation Summit in Boston), supplemented by an active newsroom and a B2B website positioning.

Oddifact's primary customer segments are pharmaceutical and biotech companies seeking to expand into rare disease indications and the 300 million+ global rare disease patient population, 95% of whom have no approved treatment. While the company's regulatory throughput is exceptional for its size, the absence of disclosed revenue, funding, or commercialized products means financial maturity lags its regulatory and reputational maturity.

Short descriptiontext

Oddifact is a Paris-based AI biotech platform that uses artificial intelligence to reposition existing drugs into approved orphan drug treatments for rare diseases, serving pharmaceutical and biotech companies. It holds 14 US/EU Orphan Drug Designations and ranks #1 globally for FDA ODDs in 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repositioning platform, orphan drug development, rare disease therapeutics, AI drug discovery, orphan drug designation
Industry2 codes
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI-driven orphan drug repositioning platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Orphan Drug Development Services
TypeLicensing Royalties
Description

AI-powered platform services for pharmaceutical companies seeking to reposition existing drugs for rare disease applications. Revenue likely derived from licensing technology, strategic partnerships, and milestone payments.

oddifact.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Oddifact operates an AI-driven platform that identifies, validates, and accelerates regulatory pathways for repurposing existing drugs as therapies for rare diseases. The company helps pharmaceutical and biotechnology firms shorten the development timeline for orphan drug indications by combining artificial intelligence with regulatory expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 73% workflow automation with AI
+3 more records
Product overview1 text field

Oddifact operates as a single unified AI-driven platform for drug repositioning in rare diseases. The core offering is an AI platform that identifies orphan drug applications for existing medicines, validates these opportunities, and accelerates regulatory pathways to turn off-label use into approved orphan drugs. The platform is supported by strategic collaborations with biotech partners like Mabion S.A. for specific drug programs.

Product and service1 record
1Oddifact AI Orphan Drug Repositioning Platform
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Polish biotech Mabion signed a letter of intent with Oddifact to explore MabionCD20 as a treatment for rare diseases, reopening a program previously developed as a rituximab biosimilar. The agreement leverages Mabion's antibody development and manufacturing expertise alongside Oddifact's AI platform designed to identify orphan drug applications for existing medicines. This partnership marks a strategic pivot for the CD20 asset, potentially opening a new market pathway through the rare disease space.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Biovista
TypeEmerging player
Description

Drug repositioning company using AI to identify new indications for existing drugs. Directly comparable to Oddifact's repositioning methodology, particularly for rare and orphan diseases.

TypeEmerging player
Description

AI-driven small molecule discovery company using structure-based design. Comparable in applying AI to accelerate early-stage drug development, though focused on novel chemistry.

TypeRegional player
Description

French AI-biotech company applying machine learning to biomedical research and drug development. Comparable as a French AI-healthcare peer, though more focused on data analysis than repositioning.

TypeRegional player
Description

Paris-based AI company specializing in generative chemistry and small molecule design. Comparable to Oddifact as a French AI-biotech peer, though focused on de novo design rather than repositioning.

TypeDirect peer
Description

AI-driven drug discovery platform combining machine learning with high-throughput biology to develop therapeutics. Comparable to Oddifact's AI-first approach to drug development.

6Pharnext
TypeDirect peer
Description

French biotech focused on drug repositioning (pleotherapy) for rare neurological diseases. Comparable to Oddifact in both the repositioning methodology and French/European origin.

TypeDirect peer
Description

AI-native pharmatech company using AI to design and develop new drug candidates. Comparable in applying AI to compress drug discovery timelines, though focused more on novel chemistry than repositioning.

TypeDirect peer
Description

AI-driven drug discovery company with a focus on identifying new uses for existing molecules and rare disease indications. Directly comparable to Oddifact's repositioning approach and AI-native platform strategy.

TypeDirect peer
Description

AI-enabled drug discovery platform combining high-throughput biology with machine learning. Comparable to Oddifact in using AI to accelerate drug identification and pipeline development across multiple therapeutic areas.

TypeDirect peer
Description

AI-driven rare disease drug discovery company focused on drug repurposing. Closely aligned with Oddifact's positioning at the intersection of AI, drug repositioning, and rare disease therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oddifact

AI-driven orphan drug repositioning platformoddifact.com

Oddifact is a Paris-based AI biotech platform that uses artificial intelligence to reposition existing drugs into approved orphan drug treatments for rare diseases, serving pharmaceutical and biotech companies. It holds 14 US/EU Orphan Drug Designations and ranks #1 globally for FDA ODDs in 2024.

What Oddifact does

Oddifact is a privately held French biotech technology company headquartered in Paris that operates an artificial intelligence platform for drug repositioning in rare diseases. The platform identifies orphan drug applications for existing medicines, validates candidates, and accelerates regulatory pathways to convert off-label use into approved orphan drug designations. The company claims 73% workflow automation through AI and the ability to move from candidate selection to FDA submission in 10 days, with an operational track record of 11 granted Orphan Drug Designations across the US and Europe, 16 FDA submissions, and a #1 global ranking for FDA Orphan Drug Designations in 2024. Its pipeline is organized around repositioning established molecules such as infliximab (for IVIG-resistant Kawasaki disease) and the MabionCD20 antibody (under a 2026 letter of intent with Mabion S.A.), with a stated ambition of 30-50 new rare disease treatments by 2030.

The business model is B2B, targeting pharmaceutical and biotech companies through direct enterprise partnerships and strategic co-development agreements, with revenue expected to derive from licensing, royalties, and milestone payments. The company operates with 11-50 employees and is founder-led by Pierre-Alexandre Teulié, with no disclosed external institutional investors, funding rounds, or revenue figures. Distribution is conducted through direct field sales and high-profile industry engagement (e.g., Digital Health & AI Innovation Summit in Boston), supplemented by an active newsroom and a B2B website positioning.

Oddifact's primary customer segments are pharmaceutical and biotech companies seeking to expand into rare disease indications and the 300 million+ global rare disease patient population, 95% of whom have no approved treatment. While the company's regulatory throughput is exceptional for its size, the absence of disclosed revenue, funding, or commercialized products means financial maturity lags its regulatory and reputational maturity.

Oddifact firmographics

Firmographics
Name
Oddifact
Legal name
Oddifact
Website
https://oddifact.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Oddifact is a Paris-based AI biotech platform that uses artificial intelligence to reposition existing drugs into approved orphan drug treatments for rare diseases, serving pharmaceutical and biotech companies. It holds 14 US/EU Orphan Drug Designations and ranks #1 globally for FDA ODDs in 2024.
Ownership category
akta.pro rank

Oddifact industry classification

Industry
Product category
AI-driven orphan drug repositioning platform
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)

Keywords

  • Drug repositioning platform
  • Orphan drug development
  • Rare disease therapeutics
  • AI drug discovery
  • Orphan drug designation

Where Oddifact is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Oddifact business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Orphan Drug Development Services: AI-powered platform services for pharmaceutical companies seeking to reposition existing drugs for rare disease applications. Revenue likely derived from licensing technology, strategic partnerships, and milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Oddifact product offering

Product offering

Core offering

Oddifact operates an AI-driven platform that identifies, validates, and accelerates regulatory pathways for repurposing existing drugs as therapies for rare diseases. The company helps pharmaceutical and biotechnology firms shorten the development timeline for orphan drug indications by combining artificial intelligence with regulatory expertise.

Product overview

Oddifact operates as a single unified AI-driven platform for drug repositioning in rare diseases. The core offering is an AI platform that identifies orphan drug applications for existing medicines, validates these opportunities, and accelerates regulatory pathways to turn off-label use into approved orphan drugs. The platform is supported by strategic collaborations with biotech partners like Mabion S.A. for specific drug programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oddifact AI Orphan Drug Repositioning Platform

Quantifiable outcome

  • 73% workflow automation with AI
  • +3 more outcomes

Companies that use Oddifact

Customer profile

Segments2 records

Ideal customer profiles1 record

Oddifact technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Oddifact partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mabion S.A.coreStrategic or Co-development Partner · 17 June 2026Polish biotech Mabion signed a letter of intent with Oddifact to explore MabionCD20 as a treatment for rare diseases, reopening a program previously developed as a rituximab biosimilar. The agreement leverages Mabion's antibody development and manufacturing expertise alongside Oddifact's AI platform designed to identify orphan drug applications for existing medicines. This partnership marks a strategic pivot for the CD20 asset, potentially opening a new market pathway through the rare disease space.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Oddifact competitors and assessment

Company assessment

Emerging players

  • Biovista: Drug repositioning company using AI to identify new indications for existing drugs. Directly comparable to Oddifact's repositioning methodology, particularly for rare and orphan diseases.
  • Atomwise: AI-driven small molecule discovery company using structure-based design. Comparable in applying AI to accelerate early-stage drug development, though focused on novel chemistry.

Regional players

  • Owkin: French AI-biotech company applying machine learning to biomedical research and drug development. Comparable as a French AI-healthcare peer, though more focused on data analysis than repositioning.
  • Iktos: Paris-based AI company specializing in generative chemistry and small molecule design. Comparable to Oddifact as a French AI-biotech peer, though focused on de novo design rather than repositioning.

Direct peers

  • Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology to develop therapeutics. Comparable to Oddifact's AI-first approach to drug development.
  • Pharnext: French biotech focused on drug repositioning (pleotherapy) for rare neurological diseases. Comparable to Oddifact in both the repositioning methodology and French/European origin.
  • Exscientia: AI-native pharmatech company using AI to design and develop new drug candidates. Comparable in applying AI to compress drug discovery timelines, though focused more on novel chemistry than repositioning.
  • BenevolentAI: AI-driven drug discovery company with a focus on identifying new uses for existing molecules and rare disease indications. Directly comparable to Oddifact's repositioning approach and AI-native platform strategy.
  • Recursion Pharmaceuticals: AI-enabled drug discovery platform combining high-throughput biology with machine learning. Comparable to Oddifact in using AI to accelerate drug identification and pipeline development across multiple therapeutic areas.
  • Healx: AI-driven rare disease drug discovery company focused on drug repurposing. Closely aligned with Oddifact's positioning at the intersection of AI, drug repositioning, and rare disease therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Oddifact social profiles

Digital presence

Oddifact financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oddifact leadership team

Management profile

Number of profiles

Profiles1 record

Oddifact funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oddifact M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oddifact

What does Oddifact do?

Oddifact operates an AI-driven platform that identifies, validates, and accelerates regulatory pathways for repurposing existing drugs as therapies for rare diseases. The company helps pharmaceutical and biotechnology firms shorten the development timeline for orphan drug indications by combining artificial intelligence with regulatory expertise.

Is Oddifact a public or private company?

Oddifact is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oddifact founded?

Oddifact was founded in -1. It employs 1 to 10 people.

Where is Oddifact based?

Oddifact is headquartered in Paris, France, in the Europe region.

How does Oddifact make money?

One revenue line is on record: orphan Drug Development Services.

Who are Oddifact's main competitors?

Emerging players on record are Biovista and Atomwise. Regional players are Owkin and Iktos. Direct peers are Insitro, Pharnext, Exscientia, BenevolentAI, Recursion Pharmaceuticals and Healx.

Does Oddifact have an API?

No public API is recorded for Oddifact.

What industry is Oddifact in?

Oddifact's product category is AI-driven orphan drug repositioning platform. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies, with a secondary code of HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageOddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune ThrombocytopeniaOddifact SAS and Mabion S.A. announced on August 26, 2026 that the FDA granted a Type B pre-IND meeting for RTX-NP (MabionCD20), a rituximab product for adult patients with persistent or chronic primary immune thrombocytopenia. The FDA opened Pre-IND file PIND 183961 under Oddifact's name, engaging the Division of Nonmalignant Hematology. The companies plan to use the meeting to align on development questions before BLA submission.BioSpaceOddifact and Mabion Receive FDA Pre-IND Meeting Grant for RTX-NP (MabionCD20) in Immune ThrombocytopeniaThe FDA granted a Type B pre-IND meeting for RTX-NP (MabionCD20), a rituximab product for adult patients with persistent or chronic primary immune thrombocytopenia. The meeting enables alignment on development strategy, and the companies aim to bring the first FDA-approved rituximab for this indication.The Pharma LetterMabion turns to Oddifact in rare disease push for CD20 assetPolish biotech Mabion has signed a letter of intent with French TechDev company Oddifact to explore MabionCD20 as a treatment for rare diseases, reopening a program previously developed as a rituximab biosimilar. The agreement leverages Mabion's antibody development and manufacturing expertise alongside Oddifact's artificial intelligence platform designed to identify orphan drug applications for existing medicines. This partnership marks a strategic pivot for the CD20 asset, potentially opening a new market pathway through the rare disease space.GlobeNewswireODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki DiseaseODDIFACT announced that the European Commission granted Orphan Drug Designation for infliximab for the treatment of Kawasaki disease, following a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products. This designation follows a previous FDA Orphan Drug Designation for the same indication, establishing a transatlantic regulatory foundation for infliximab as a treatment for IVIG-resistant Kawasaki disease in children.GlobeNewswireODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de KawasakiODDIFACT, a French TechDev company specializing in drug repositioning for rare diseases using artificial intelligence, has received orphan drug designation from the European Commission for infliximab in the treatment of Kawasaki disease, following prior FDA orphan drug designation for the same indication. The KIDCARE Phase III clinical trial demonstrated infliximab's superiority over standard retreatment in IVIG-resistant Kawasaki disease patients, showing shorter fever duration, reduced need for rescue therapy, and shorter hospital stays. Kawasaki disease is the leading cause of acquired heart disease in children in developed countries, with 10-20% of patients resistant to standard IVIG treatment and approximately 25% developing coronary artery aneurysms without prompt treatment.PR NewswirePierre-Alexandre Teulié of Oddifact Wins 2025 Business Worldwide Magazine CEO AwardPierre-Alexandre Teulié, founder and CEO of Oddifact, was recognized by Business Worldwide Magazine as the "Most Innovative CEO in Rare Disease Research & Treatment Development" in its 2025 CEO Awards, celebrating his leadership at the intersection of artificial intelligence and biomedicine. In 2024, Oddifact received more Orphan Drug Designations from the U.S. FDA than any other biopharmaceutical company worldwide, demonstrating the company's ability to dramatically cut the cost, time, and risk of traditional pharmaceutical R&D for rare diseases. The company is pursuing international partnerships with the goal of bringing 50 new rare disease treatments to market by 2030.